GSK-2324 manufacturers
- GSK2324
-
- $342.00
-
2026-07-27
- CAS:1020567-30-9
- Purity: 99.76%
- Supply Ability: 10g
|
| | GSK-2324 Basic information |
| Product Name: | GSK-2324 | | Synonyms: | GSK-2324;2-Quinolinecarboxylic acid, 6-[4-[[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methoxy]phenyl]- | | CAS: | 1020567-30-9 | | MF: | C29H22Cl2N2O4 | | MW: | 533.4 | | EINECS: | | | Product Categories: | | | Mol File: | 1020567-30-9.mol |  |
| | GSK-2324 Chemical Properties |
| Boiling point | 698.1±55.0 °C(Predicted) | | density | 1.351±0.06 g/cm3(Predicted) | | pka | 1.21±0.30(Predicted) |
| | GSK-2324 Usage And Synthesis |
| Description | GSK2324 is a FXR agonist (EC50 = 50 nM, 102% efficacy). | | Uses | GSK2324 (Compd 1c) is a FXR agonist for diabetes study, with an EC50 of 120 nM. GSK2324 exhibits t1/2 values of 84 min (mouse), 170 min (rat), 110 min (beagle) and 120 min (cyno), respectively[1]. | | References | [1] Jonathan Y Bass, et al. Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene. Bioorg Med Chem Lett. 2011 Feb 15;21(4):1206-13. DOI:10.1016/j.bmcl.2010.12.089 |
| | GSK-2324 Preparation Products And Raw materials |
|